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This article, written by members
of the International Union of
Basic and Clinical Pharmacology
Committee on Receptor
Nomenclature and Drug
Classification (NC-IUPHAR)
subcommittee for the opioid
receptors, confirms the existing
nomenclature for these receptors
and reviews our current
understanding of their structure,
pharmacology and functions and
their likely physiological roles in
health and disease. More
information on this receptor
family can be found in the
Concise Guide to Pharmacology
(http://onlinelibrary.wiley.com/
doi/10.1111/bph.12445/abstract)
and for each member of the
family in the corresponding
database. http://www
.guidetopharmacology.org/
GRAC/FamilyDisplayForward?
familyId=50&familyType=GPCR
Recent developments in the study of the structure and function of opioid receptors
raise significant challenges for the definition of individual receptor types and the
development of a nomenclature that precisely describes isoforms that may subserve
different functions in vivo. Presentations at the 2013 meeting of the International
Narcotics Research Conference in Cairns, Australia, considered some of the new
discoveries that are now unravelling the complexities of opioid receptor signalling.
Variable processing of opioid receptor messenger RNAs may lead to the presence of
several isoforms of the μ receptor. Each opioid receptor type can function either as
a monomer or as part of a homo- or heterodimer or higher multimer. Additionally,
recent evidence points to the existence of agonist bias in the signal transduction
pathways activated through μ receptors, and to the presence of regulatory allosteric
sites on the receptors. This brief review summarizes the recent discoveries that raise
challenges for receptor definition and the characterization of signal transduction
pathways activated by specific receptor forms.
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Links to online information in IUPHAR-DB and the BPS Concise Guide to
PHARMACOLOGY
Targets Ligands
5-Hydroxytryptamine receptors (serotonin receptors) α-neoendorphin
μ receptor β-endorphin
δ receptor dynorphin A
κ receptor dynorphin B
NOP receptor enkephalins
Chemokine receptors N/OFQ
GPCR naloxone
orexin-A
orexin-B
OT
LIMK1
LIMK2
ROCK1
ROCK2
TLR4
This table lists chemical names, words and phrases that are hyperlinked to relevant entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014; PMID: 24234439) and the Concise Guide
to PHARMACOLOGY 2013/14 (http://onlinelibrary.wiley.com/doi/10.1111/bph.2013.170.issue-8/issuetoc, Alexander et al., 2013).
Almost two decades ago, the International Union of Basic and
Clinical Pharmacology (IUPHAR) established a nomenclature
committee to standardize the definitions and characterize the
properties of receptors activated by neurotransmitters, hor-
mones, cytokines and many drugs – this committee is known
by the acronym NC-IUPHAR. In turn, NC-IUPHAR estab-
lished subcommittees to make recommendations on specific
receptors and to develop a database defining the receptor
systems and drug targets coded by the human genome with
references to the most appropriate experimental models and
the best selective radioligands, agonists and antagonists. This
database can be found at http://www.iuphar-db.org; it is a
mine of useful information for almost all receptors and ion
channels.
The well-established Greek symbol terminology, μ, δ and
κ, for the first three types of opioid receptors to be identified
was proposed by Bill Martin, Hans Kosterlitz and their
co-workers (Gilbert and Martin, 1976; Martin et al., 1976;
Lord et al., 1977) in the mid-1970s. In 1996, an alternative
terminology was proposed by an NC-IUPHAR subcommittee
(Dhawan et al., 1996), but this terminology was not accepted
by the field and is no longer used. A reconstituted Opioid
Receptor Nomenclature Subcommittee (ORNS) proposed a
return to the original nomenclature for opioid receptors, and
added additional recommendations relating to the opioid
receptor family (OP) and the receptor that is selectively acti-
vated by the endogenous ligand, nociceptin/orphanin FQ
(abbreviated here as N/OFQ). The recommended revised ter-
minology and abbreviations were accepted by NC-IUPHAR,
and can be found on the NC-IUPHAR website: http://
www.guidetopharmacology.org/GRAC/FamilyIntroduction
Forward?familyId=50. The recommended nomenclature is
briefly summarized in Table 1.
The close structural homologies between the three classic
types of opioid receptors, μ, δ and κ, and the more recently
discovered receptor for N/OFQ have been confirmed by the
recent reports of the crystal structures of each of these recep-
tors when complexed with antagonists (Granier et al., 2012;
Manglik et al., 2012; Thompson et al., 2012; Wu et al., 2012).
They are clearly members of one family of proteins, with
differences between the receptor types arising by gene dupli-
cation events during evolution. It is thus appropriate to group
these receptors as a single receptor family. NC-IUPHAR policy
is to name receptors after their endogenous ligands, and to
require that the abbreviation selected to represent a receptor
family is two letters when there would be potential for con-
fusion with other receptors if a single letter were to be used.
Given the existence of receptors for oxytocin and orexins, the
family name selected by NC-IUPHAR for opioid receptors is
OP (i.e. opioid peptide receptors). The Greek symbol termi-
nology for the three receptors of the OP that were first dis-
covered, μ, δ and κ, is retained, so these become the μ
receptor, the δ receptor and the κ receptor (or μOP receptor,
δOP receptor and κOP receptor). Because it is sometimes
inconvenient or impractical to use the Greek symbols, alter-
native abbreviations recognized by NC-IUPHAR are MOP,
DOP and KOP. By analogy, the fourth member of the family
becomes the NOP receptor (for nociceptin opioid peptide
receptor). Note that in the NC-IUPHAR system the letter R for
receptor is never used as part of the receptor name as this
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adds no information to the terminology; the context usually
makes clear that the terminology refers to a receptor. The
widely used abbreviations MOR, DOR and KOR are therefore
inconsistent with the NC-IUPHAR standards for receptor
nomenclature; the ORNS recommends that these abbrevia-
tions should not be used to describe opioid receptor types. A
summary of the recommended nomenclature and abbrevia-
tions for opioid receptor types is presented in Table 1.
Some investigators have questioned whether the NOP
receptor should be classified as a member of the OP family,
perhaps influenced by Hans Kosterlitz’s dictum, frequently
repeated by him at International Narcotics Research Confer-
ence (INRC) meetings during the 1970s and 1980s, that if a
receptor-mediated action is not antagonized by naloxone,
then the action should not be called an opioid receptor-
mediated effect. This insistence on a rigid procedural defini-
tion of an ‘opioid’ was valuable at the time. For example, it
became apparent that the actions of drugs at the sigma recep-
tor, originally identified by Bill Martin as an opioid receptor
(Gilbert and Martin, 1976; Martin et al., 1976), were not
antagonized by naloxone (in contrast to Martin’s original
claim) and should not be called opioid. Subsequent studies
have established that the sigma receptor exists, but as a
protein that is very different in structure and function from
the μ, δ and κ receptors (Seth et al., 1998). Furthermore, many
of the ligands that activate this receptor have very different
structures from the endogenous ligands for the opioid recep-
tors (Hayashi and Su, 2005). Kosterlitz’s dictum need not be
applied to the entire OP receptor family. The NOP receptor,
unlike sigma receptors, is very similar in structure and in
most functions to the other OP receptors. Actions of N/OFQ
through the NOP are not antagonized by naloxone, but the
amino acid sequence of N/OFQ indicates that this peptide is
closely related structurally to the endogenous opioid pep-
tides, probably derived during evolution by gene duplications
among the opioid peptide gene family in much the same way
as the various OP receptor forms diverged by gene duplica-
tion during evolution (Nothacker et al., 1996). As noted
earlier, the NOP receptor crystal structure closely resembles
the crystal structures of the μ, δ and κ receptors and is closer
to these than to other GPCRs. Thus, in contrast to sigma
receptors, NOP receptors display primary, secondary and ter-
tiary structural similarity to other members of the OP recep-
tor family, and are activated by an endogenous ligand that
has a primary structure that is closely related to that of the
endogenous ligands for the μ, δ and κ receptors. Additionally,
the NOP receptor employs a repertoire of signal transduction
pathways that is very similar to the set of pathways activated
by the three classic opioid receptors. These structural and
functional considerations trump the absence of sensitivity to
naloxone antagonism and clearly necessitate the assignment
of the NOP receptors to the OP receptor family. The NOP
receptor should be considered a subcategory of the OP recep-
tor family with atypical low affinity for the classic opioid
peptides (the enkephalins, β-endorphin and dynorphin) and
insensitivity to antagonism by naloxone.
Several issues that have implications for opioid receptor
classification and nomenclature were discussed during the
2013 INRC meeting. An area with potential significance for
OP receptor classification is the growing evidence that the
Table 1
NC-IUPHAR-approved nomenclature for opioid peptide receptors
Current NC-IUPHAR-
approved nomenclaturea
Other (non-approved)
nomenclature Presumed endogenous ligand(s)
μ, mu or MOP MOR, OP3 β-Endorphin (not selectivec)
Enkephalins (not selectivec)
Endomorphin-1b
Endomorphin-2b
δ, delta or DOP DOR, OP1 Enkephalins (not selectivec)
β-Endorphin (not selectivec)
κ, kappa or KOP KOR, OP2 Dynorphin A
Dynorphin B
α-Neoendorphin
NOP ORL1, OP4 Nociceptin/orphanin FQ
(N/OFQ)
Receptors activated by opiate drugs respond physiologically to endogenous opioid peptides; they are therefore opioid peptide receptors, the
receptor family being designated by the two-letter abbreviation OP.
aThe well-established Greek terminology for opioid receptor types using the descriptors μ, δ and κ is recommended, but where Greek symbols
are not permitted or impractical, the use of mu, delta or kappa, or MOP, DOP or KOP is permissible.
bNo mechanism for the endogenous synthesis of endormorphins has been identified; their status as endogenous ligands for the μ receptor is
tentative.
c‘Not selective’ indicates that these ligands are not strongly selective for the specific receptor types indicated; they may have sufficient affinity
and efficacy at other opioid receptors to exert pharmacological effects through the non-preferred site. For example, the enkephalins are listed
as non-selective ligands for both μ and δ receptors. However, all ligands in this table have very low affinity and efficacy at non-opioid GPCRs.
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signal transduction pathways that are activated by agonists
acting at the same receptor type are not always identical.
Evidence that individual agonist ligands may preferentially
direct the functional response elicited by their common
receptor to different transduction pathways was the subject of
a plenary lecture by Arthur Christopoulos on biased agonism
at GPCRs. The main emphasis of Christopoulos’s talk was on
other GPCRs, not specifically on opioid receptors, but other
speakers addressed biased agonism at OP receptors. Eamonn
Kelly from Bristol showed unambiguously that certain ago-
nists at MOP receptors bias the response towards either
G-protein- or β-arrestin-mediated transduction pathways.
The signalling pathway repertoire that can be activated by
these transducers is also expanding. For example, Wendy
Walwyn presented evidence that δ and NOP receptors can
activate cofilin, an actin-modulating protein, via β-arrestin,
Rho-kinase (ROCK) and Lim domain kinase (LIMK). Until
recently, it had been assumed that any ligand that could
activate a receptor would induce essentially the same cellular
response, with the major differences in response relating to
the relative efficacies of different agonists. Now that biased
agonism at OP receptors is an established fact, apparent dif-
ferences in the responses induced by agonists that act at the
same receptor type do not require the postulation of separate
receptor subtypes for each agonist; the same receptor may be
differentially biased by each agonist to mediate different
transduction pathways.
Functional studies of OP receptors in the 1980 and 1990s
suggested the existence of subtypes of the major OP receptor
forms; specifically, differences in the relative potencies of
selected agonists at δ receptors and their differential sensitivi-
ties to certain antagonists led to claims of the existence of
subtypes of δ receptor (see review by Zaki et al., 1996). At μ
receptors, the actions of some agonists are reported to be
more readily antagonized by the irreversible antagonist,
naloxonazine, than others (Pasternak and Wood, 1986; Paul
et al., 1989). These observations led to the proposal that there
are subclasses of δ and μ receptor, named δ1, δ2, μ1 and μ2, but
no evidence for the existence of more than one gene for the
δ or μ receptors exists despite careful homology searches of
the genome. Knockout of the δ receptor gene is reported to
abolish the activity of ligands preferentially acting at both δ1
and δ2 sites (Filliol et al., 2000). There are also proposals for
the existence of subtypes of κ receptor, based on relative
agonist potencies for selected actions that appear to be medi-
ated by κ receptors (Rothman et al., 1989). However, a triple
knockout of μ, δ and κ receptors completely abolishes binding
and function of all opioid ligands (Clarke et al., 2002; Martin
et al., 2003), indicating that these ligands require at least one
of the three receptor members of the OP receptor family for
activity.
It is possible that some or all of the data leading to the
proposal that there are subtypes of μ, δ and κ receptors might
be explained by biased agonism. Agonist potency ratios are
now only interpretable if the experimental system from
which the data are obtained is fully defined, including not
only the receptor type mediating the actions, but also the cell
type(s), the experimental conditions and the signal transduc-
tion systems mediating the measured effects. Examining dif-
ferences in the relative potencies of a series of agonists in
different cell or tissue preparations or in vivo was historically
an important approach to the identification of heterogeneity
of many receptor types. It was this type of evidence that was
used in part to support the proposed δ receptor subtypes (Zaki
et al., 1996). However, because of the possibility of biased
agonism, differential agonist potency or efficacy can no
longer be regarded as strong enough evidence to postulate the
existence of non-identical receptors as the mediators of these
actions, although antagonist dissociation constants continue
to provide more robust evidence of receptor heterogeneity.
These conclusions have significance for the receptor data-
bases. Agonist potency ratios are of value in the context of
highly defined experimental systems but must be interpreted
with caution. The possible existence of opioid receptor sub-
types should be re-examined in the light of recent studies
demonstrating biased agonism at opioid receptors.
Apparent receptor heterogeneity might also be induced
by interactions of receptors with interacting proteins or
modulating ligands. Cvejic and Devi (1997) and her col-
leagues reported that OP receptors could form homodimers,
and in 1999 they showed the formation of functional het-
erodimers with ligand-binding properties that differed from
those displayed by either of the individual receptor types
(Jordan and Devi, 1999). In the case of the δ−κ receptor
heterodimer, the ligand-binding properties were found to
match the properties of the putative κ2 subtype (Zukin et al.,
1988). Subsequently, many other groups have confirmed the
existence of opioid receptor dimers and higher order forms
(oligomers), and the observation has been extended to many
other GPCRs (Milligan, 2009). Indeed, several non-opioid
GPCRs including chemokine and serotonin receptors have
now been reported to form functional heterodimers with
opioid receptors (Hebert, 2008; Rozenfeld and Devi, 2011;
Cussac et al., 2012). But to date it has not been unambigu-
ously demonstrated that the reported μ, δ and κ receptor
heterogeneity can be accounted for by receptor heterodi-
merization. Towards this end, reagents that allow detection
and evaluation of the endogenous OP heterodimers are
being generated and these have begun to show promising
results; δ−μ heterodimer-selective antibodies have been
useful in revealing morphine-induced up-regulation of this
heterodimer in the brain and in demonstrating heterodimer-
directed signal trafficking (Rozenfeld and Devi, 2007; Gupta
et al., 2010). Ligands selectively targeting the heterodimer
have helped demonstrate allosteric modulation of ligand
binding and signalling by heterodimerization (Gomes et al.,
2011; 2013) as well as the exploration of the pharmacologi-
cal properties of heterodimers in vivo (Daniels et al., 2005;
Milan-Lobo et al., 2013). Finally, cell-permeable peptides
that selectively disrupt the δ−μ heterodimer have helped
address the contribution of this heterodimer to opioid phar-
macology (He et al., 2011). Reagents such as these will be
valuable in addressing the extent to which receptor hetero-
geneity could be attributed to opioid receptors heterodimers
in biological systems.
Agonist actions at many GPCRs are additionally subject to
either positive or negative regulation by ligands acting
through allosteric regulatory sites on the GPCR. The exist-
ence of allosteric modulators of the μ receptor (Burford et al.,
2013) was discussed at the meeting by Andrew Alt and John
Traynor. Positive and negative allosteric compounds binding
to a GPCR change receptor conformation to either enhance
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or inhibit orthosteric agonist binding and receptor activa-
tion; positive allosteric modulators may also show agonist
effects, such compounds are allosteric agonists. A key finding
is that the allosteric modulator-occupied receptor can have
differential affinity for some, but not all orthosteric ligands,
resulting in probe dependence; moreover, the allosteric
modulator may induce, or change the direction of, signalling
bias. Thus, differential sensitivity of the activation of recep-
tors by diverse agonists to allosteric regulation offers another
potential explanation for the apparent differences in the
actions of different agonists at the same receptor. These obser-
vations point to the need for additional research describing
more completely allosteric modulatory sites on each OP
receptor. Because there are changes in relative agonist affinity
and/or efficacy, and perhaps induction of a signalling bias,
the allosteric modulator-bound receptor may be considered a
novel entity. On the other hand, allosteric modulators only
subtly alter receptor conformation and so an OP receptor
bound to an allosteric modulator remains an OP receptor,
based on the structural and functional arguments discussed
earlier. Nonetheless, the fact that allosteric modulators can
differentially change the ability of agonists to bind to and
activate the receptor and may have agonist actions on their
own presents new challenges for OP receptor nomenclature,
and in particular for opioid ligand nomenclature.
The role of alternative transcription from a single gene as
a potential basis for OP receptor subtypes is also controver-
sial. Gavril Pasternak and others have shown that there is
more than one transcription start site on the μ receptor gene
and multiple alternative mRNA splicing pathways, resulting
in multiple transcripts coding for proteins with different
primary structures (Abbadie et al., 2000; Koch et al., 2001;
Kvam et al., 2004). It is suggested that these variant receptor
forms can account for the apparent functional heterogeneity
of μ receptors (Pasternak and Pan, 2013). There are no reports
of multiple start sites and alternative transcripts for the δ and
κ receptor genes. Thus, the alternative transcript hypothesis is
only plausible as a potential explanation for the apparent
heterogeneity of μ receptors but, with few exceptions (e.g. Liu
et al., 2011), there remains much uncertainty about the levels
of expression of the variant mRNA forms for this receptor,
their stability in the cell and the properties of any proteins
expressed from these mRNA variants. The presence of func-
tional receptor proteins derived from variant transcripts
(arising from different transcription start sites or alternative
mRNA splicing) from a single receptor gene requires further
study. If confirmed then a consistent nomenclature differen-
tiating the variant forms of a single receptor will need to be
developed.
Sequence variations within opioid receptor genes might
cause the expressed receptors to display properties that dis-
tinguish these receptors from those of the most frequently
expressed receptor form. There are numerous single nucleo-
tide polymorphisms in human opioid receptor genes, but
most are rare and none are known to alter the conformations
of the expressed receptor (Mague and Blendy, 2010). Only
one polymorphism in the coding region of human opioid
receptor genes is known to occur with relatively high fre-
quency (rs 1799971; varying from 40 to 50% in some Asian
populations to 5% or less in African Americans; Gelernter
et al., 1999), and its known functional consequences are
limited. A change of adenosine to guanosine in position 118
(A118G) of the coding region (exon 1) of the human MOP
gene results in the expression of a receptor with aspartic acid
(Asp) in position 40 instead of asparagine (Asn); this change
removes a potential glycosylation site. A transgenic mouse
line in which guanosine is replaced by adenosine in the
equivalent position of the mouse μ receptor gene (A112G,
expressing N38D) resulted in expression of receptors with
similar ligand-binding properties but reduced levels of
expression of the receptor mRNA and reduced receptor
protein levels relative to the wild-type receptor (Mague et al.,
2009). This is consistent with other reports that downstream
signalling is impaired in the variant form relative to the
wild-type human μ receptor (Mague and Blendy, 2010; Oertel
et al., 2012). The mechanism for the reduced level of expres-
sion may relate to increases in methylation of the 118G μ
receptor gene. Oertel et al. (2012) report that the degree of
gene methylation at positions +117 and adjacent down-
stream methylation sites was higher in heroin-using subjects
expressing the 118G variant than in 118A expressing sub-
jects. In 118G subjects, chronic heroin use was not associated
with elevated levels of μ receptor expression, but in 118A
subjects chronic heroin use induced an up-regulation of μ
receptor expression in the thalamus and a cortical region.
Increased receptor methylation in the 118G receptor gene
may impede receptor up-regulation in response to drug expo-
sure, suggesting an epigenetic regulation of the level of
expression of μ receptors (Oertel et al., 2012). This work
requires confirmation in a larger set of subjects. To date,
however, there are no reports indicating that functional
opioid receptors with altered ligand binding or signal trans-
duction properties are produced as a result of polymorphisms
in opioid receptor genes.
Some opioid drugs have been reported to bind to non-
opioid receptor proteins such as filamin A, which interacts
directly with μ receptors (Wang et al., 2008), or to the Toll-like
receptor-4 (TLR-4) (Hutchinson et al., 2011) that does not
interact directly with opioid receptors. Naturally, the struc-
tural requirements for interaction of opioids with these pro-
teins are very different from their binding to classical opioid
receptors. Nonetheless, the interactions might be important,
for example, direct actions of opioids on the TLR-4 complex
have been proposed to activate microglia to mediate many of
the adverse effects of morphine (Hutchinson et al., 2011).
However, this potential mechanism has been ruled out in
other studies of morphine-induced microglial activation
(Ferrini et al., 2013; Fukagawa et al., 2013), and the affinity of
interaction of opioids with TLR-4 mechanisms is at least
several orders of magnitude weaker than their interaction
with MOP (Wang et al., 2012), questioning their pharmaco-
logical relevance. Thus, the functional relevance of binding
of some opioid drugs to proteins other than the opioid recep-
tors is not clearly established. As these interactions do not
involve direct binding to opioid receptors, it is not feasible to
define them within the framework of an opioid receptor
nomenclature, but investigators need to be aware that ligands
for opioid receptors, like many other receptor ligands, can
interact with other proteins with possible functional conse-
quences, whether with very high affinity as for filamin A
(Wang et al., 2008) or with low affinity as for TLR-4 (Wang
et al., 2012).
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Concluding comments
There has been a growing consensus on the use of recom-
mended opioid receptor nomenclature shown in Table 1
since the publication of the most recent NC-IUPHAR recom-
mendation. If and until the accepted nomenclature for opioid
receptors is revised to encompass the proposed variant forms
of μ, δ and κ receptors based on more stringent criteria that
take into account the additional variables in receptor prop-
erties outlined earlier, we suggest that the simple classifica-
tion in Table 1 be used by all authors.
Beyond μ, δ, κ and NOP receptors, a description of opioid
receptor subtypes such as μ1 or μ2 is not recommended unless
they are described as putative. We do not consider that the
evidence for opioid receptor subtypes that has been offered
to date provides unambiguous evidence of independent
functional receptors that are not variant forms of the major
opioid receptors. Until a new nomenclature for opioid recep-
tor variants encompassing possible alternative transcription
start sites or splice sites, receptor homo- and hetero-
multimers, positive and negative allosteric regulation, and
biased agonism is established and accepted by the research
community, any such proposed variants should be fully
described. Evidence of activation of signalling pathway(s)
not previously associated with opioid receptors, the identifi-
cation of novel allosteric regulatory site(s) and the establish-
ment of novel polymeric structures should not be considered
sufficient justification for modification of the current
nomenclature.
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